|
Compendia and Althea develop breast cancer assay as companion Dx platform
January 2011
SHARING OPTIONS:
ANN ARBOR, Mich.—Compendia Bioscience and Althea
Diagnostics
recently announced that they will develop a product and service
offering called the Breast Cancer Segregation Panel as a platform for companion
diagnostic development. The panel measures 96 genes that represent key
molecular variability of breast cancer and have been derived from a proprietary
meta-analysis of cancer genomic profiles from more than 5,000 clinical samples.
The assay has been optimized by Althea to measure the genes using
quantitative
RT-PCR from formalin-fixed tissue (FFPE) samples to enable rapid translation to
real-world clinical settings. Compendia will analyze the
data generated by the assay
and perform correlation studies to end-points of interest such as drug
response, allowing for development of multiple
drug-specific companion
diagnostics from a standardized platform. The companies also plan to develop
similar assays for other cancer disease types.
Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|